4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%

VBIV’s revenue for its fiscal 2021 first quarter, ended March 31, was $301,000, up 50.5% from the fourth quarter of 2020. Its cash used in operating activities decreased 13.2% year-over-year to $6.60 million. This decrease resulted from a change in operating working capital and notably from the cash it received in advance from the CEPI funding agreement. The company had cash and cash equivalents of $108.23 million as of March 31, 2021.

Analysts expect VBIV’s revenue to be $472,000 for the current quarter, ending June 30, 2021, which represents a 156.5% rise year-over-year. VBIV has gained 28.5% over the past year and 22.6% over the past month. VBIV ended yesterday’s trading session at $3.20.

All five Wall Street analysts that rated the stock rated it ‘Buy.’ Furthermore, the analysts expect the stock to hit $6.60 in the near term, indicating a potential 106.3% upside.

BNGO shares were trading at $5.61 per share on Friday afternoon, down $0.01 (-0.18%). Year-to-date, BNGO has gained 82.14%, versus a 11.62% rise in the benchmark S&P 500 index during the same period.

1 2 3 4
View single page >> |

Disclaimer: Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.